Analysis On Autologous Fluorescence Spectrum Of Patients With Gynecologic Tumor

Gynecologic tumors have no obvious clinical symptoms and are difficult for early diagnosis, more than 70% patients were diagnosed at advanced stage, which directly result in high mortality of these diseases. Therefore, how to diagnose them early is the key that improving cure rate of gnecologic tumors. Beause of the close relationship between blood serum and tissues, the invasion of cell metabolite and tumor marker molecule of cancer into blood can be reflected by the change of our internal environment, which may cause the variation of serum autologous fluorescence spectrum of these patients. Therefore, detecting the change of serum autologous fluorescence spectrum of tumor patients with spectrophotofluorimetry would possiblly give us the metabolic information of underlying tumor, subsequently, be useful in diagnosing a covert tumor as early as possible. Because of the promising prospective application, this technique has gained global concerns and some advance. Therefore, we test the serum autologous fluorescence spectrum of gynecologic oncological patients before or after certain treatment,and compare with the results the normal women, and further discuss the difference between the results of patients before the surgical operation or chemotherapy and after it, and give spectroscopy evidences to the early screening or curative effect of oophoroma.ObjectiveTo study the change of serum autologous fluorescence spectrum of gynecologic oncological patients and give spectroscopy evidences to the early screening or curative effect of oophoroma.Methods1 Subjects of studyChoosing primary oophoroma or hysteromyoma patients in the Second People's Hospital of Jiaozuo City from June 2008 to August 2009 as subjects of the study, and choosing physically normal people who had the routine health examination in the same hospital from June 2008 to August 2009 as control group.2 Collection of specimensDrawing fasting plasma 3ml from the normal control group, hysteromyoma patients and oophorom patients before or after surgery or chemotherapy, and then offcenter to get upper layer blood serum,keep it at 4℃.3 Detecting serum autologous fluorescence spectrumUsing Hitachi RF-4500 fluorospectrophotometer, excitation light source was xenon lamp, excitation light wave was 300nm, wave lenth of fluorescent scanning were 200～800nm, width of excitation light slit was 5nm, width of emitted light slit was 5nm, speed of scanning were 1200nm/min. Ddrawing blood serum sample 1ml, and then inject it into standard sample cisterna slowly, and then detection.After determine every sample, and use de-ionized water to wash sample cisterna.All operation carry on under room temperature, avoiding strong illumination.4 Statistic analysisAnalysing the data with SPSS13.0 statistical software.Using t test to analyze peak location, peak height,peak area of serum autologous fluorescence spectrum of all sample.Using one-way analysis of variance to analyze the data before or after surgery or chemotherapy.Results1 Compared with normal group, serum autologous fluorescence spectrum of fibroid patients had a violet shift near 330nm and intensities of the spectrum at near 302nm and near 605nm were also significantly high in fibroid patients(p<0.05).2 Compared with normal group, serum autologous fluorescence spectrum of patients with uterine cervix cancer had a violet shift near 441nm (p<0.05),and intensities of the spectrum at near 330nm and near 605nm were also significantly high in cervix cancer patients(p<0.05).3 Compared with normal group, serum autologous fluorescence spectrum of patients with endometria cancer had a red shift near 613nm (p<0.05),and both intensity of the spectrum at near 303nm and near 335nm were significantly high in endometria cancer patients(p<0.05).4 Compared with normal group, serum autologous fluorescence spectrum of patients with ovarian cancer had a red shift near 450nm and 540nm (p<0.05),and intensity of the spectrum at near 330nm and 455nm are also significantly high in ovarian cancer patients(p<0.05).The peak height of ovarian cancer group went up obviously near 545nm,compared with the normal group, have obvious difference.5 Not like data of ovarian cancer patients obtained before their surgery, data obtained after their operation shows a significantly red shifted at near 330nm(p<0.05), and a violet shift near 450nm and 550nm(p<0.05). The intensities of the spectrum at near 330nm,450nm,550nm,605nm, and 650nm were also significantly high in ovarian cancer patients who had already undergone the surgery(p<0.05).6 Similarly, serum autologous fluorescence spectrum patients with ovarian cancer who had received chemotherapy have a red shift at near 330nm(p<0.05, compared with data obtained before chemotherpy) and a violet shift at near 450nm and 550nm(p<0.05, compared with data obtained before chemotherpy). The intensities of the spectrum at near 330nm,450nm,602nm were also significantly high in ovarian cancer patients who had already undergone the chemotherpy(p<0.05).ConclusionWe observed that the serum autologous fluorescence spectrum of fibroid patients had a violet shift at near 335nm and its intensity was significantly high at 302nm; and patients with uterine cervix cancer had a violet shift at near 441nm and its intensity was high at 605nm; patients with endometria cancer had a red shift at near 610nm and its intensity was high at 302nm. There were differences in main peak location and intensity of serum autologous fluorescence spectrum of patients with ovarian cance between those who had undergone surgery or chemotherapy and those who had not. Serum autologous fluorescence spectrum changes during the onset and progress of various kinds of uterus tumor. Therefore, as for the research about autologous fluorescence spectrum of patients,analysising from the structural chemistry or Biochemistry,it showed that how specially biochemistry change when normal tussue convert into tumor, then tried to find small change of cell structure during oncogenesis, and maybe it could support the testing information before cell structure growths form tumor. Using the change of serum autologous fluorescence spectrum as a tool of founding the underlying uterus tumor would be proved useful in early-stage diagnosis and evaluation of treatment efficacy. Besides, this research had established a spectrophotofluorimetry procedure for researching and diagnosing gynecologic cancer which had been proved to be faster and simpler than traditional way. This technology could be used clinically and scientifically in the area of gynecologic oncology.